Abstract -Glycosidases are generally glycoproteins from lysosomal origin that catalyze the hydrolysis of glycoproteins, glycolipids and glycosaminoglycans, as well as synthetic substrates. They accomplish a very important role (partially known) in physiological circumstances, and their dysfunction causes pathological processes, where they have been mainly studied in connection to the lysosomal storage diseases. After a brief review on the biosynthesis and catabolism of glycosidases and the factors influencing their activity, the present review article summarizes our own results on some glycosidase activities (-N-acetylhexosaminidase, c-L-fucosidase,
INTRODUCTION
From very early times, man has taken advantage of the empirical use of several glycosidases. Biological transformation in milk, starch degradation in cereals, etc, were biochemical processes that primitive and later civilized human beings employed without knowing their mechanism. During the first half of the XIX century, several scientists (Kirchoff, Payen and Persoz, Robiquet) studied some chemical reactions implicated in such processes. Unfortunately, this promising research on glycosidases was later developed slowly for nearly 100 years.
At the middle of the fifties of the XX century a biochemical discovery would change this situation-: the finding by De Duve of a new intracellular organelle containing hydrolases, the lysosome.
On the other hand, the Clinical Enzymology was also a small chapter of the General Biochemistry in our century until the fifties. Phosphatases, lipases and amylases were the enzymes whose activities were more commonly determined with a diagnostic finality.
Immediately after the end of the second world war scientists paid a special attention to the possibility of enlarging the number of enzyme determinations which could be useful in that view. Furthermore, some artificial substrates were introduced to replace several natural ones, searching for easier and more precise determinations (performed generally by spectrophotometry)of the products released by the enzyme activity. So, progress in the enzyme techniques improved this branch of the Clinical Analysis and "Medicine could arrive, after the tissular and cellular periods, to the border of the Molecular Pathology', as it was written in 1971 (Ref. 1). Later, a new area has emerged; i.e., the determination of metabolites of high interest (glucose, uric acid, etc) by using analytical reagents containing enzymes. Enzymes are employed as analytical tools, due to their specificity and efficiency. At present,the number of enzymes employed with this finality is gradually increasing.
In contrast, it might be asked why only about twenty enzymes (among the about 2,000 characterized enzymes) are generally determined for diagnostic of some acquired diseases. Perhaps the explanations to this fact are: (i) that these twenty enzymes are very well introduced both in the routine work of clinical laboratories and in the common knowledge of practioners; and (ii) that they give a satisfactory solution for the main diagnostic problems of these diseases.
However, it seems that Enzymology can enlarge this field by searching on other enzymes such as glycosidases, taking into account the characteristics of these enzymes.
The aim of this review is to summarize only the main results concerning the glycosidases whose activity has been determined in sera or urine from patients with some acquired disease.
It seems interesting to comment briefly some features about composition, biosynthesis and catabolism of the glycosidases, to justify the use of such materials for these assays as well as the advantages and limitations of these relatively new determinations.
GLYCOSIDASES AS GLYCOPROTEINS, AND CHARACTERISTICS OF GLYCOSIDASES
As it has been recently written (2) , "glycosidases or carbohydrases are enzymes, included in class 3 of the Enzyme general clasification (IUB, 1979) that catalyze the hydrolysis of glycoconjugates (glycoproteins, glycolipids and glycosaminoglycans) as well as synthetic substrates which contain glycosidic linkages" (...).
"Some of the reasons that may explain the emergence of a new knowledge on glycosidases after the decade of 1950, are the following: (a) the large distribution of these enzymes in Nature (actually considered as ubiquitous), which indicate their relevant role; (b) the demonstration of the occurence of glycosidases mainly in lysosomes, but also in other subcellular fractions; (c) the fact that an exoglycosidase from Escherichia coli, the -galactosidase, has been employed in Molecular Biology, for informationists studies, as well as the lysozyme has been investigated in Molecular Biology for the structuralist approach; (d) the use of severl glycosidases, either partially or completely purified, as tools for the determination of glycoconjugates structures; (e) the characterization of inherited metabolic disorders in which there is deficiency either of one glyosidase or one glycosidase isoenzyme; (f) finally, the recent knowledge on the role of some monosaccharides in the half-life of the plasma glycoproteins, regulated by the liberation of these carbohydrates by some glycosidases".
Glycosidases are generally glycoproteins (except lysozyme) and very often sialoglycoproteins-. Several new reviews have appeared on glycoproteins 3-5) substances whose knowledge has been improved dramatically during the last few years. Reviews on nature and properties of glycosidases have algo been published (6, 7).
Many glycosidases exhibit multiplicity of forms,. either from genetic origin (true isoenzymes) or from nongenetic origin (see later).
Although glycosidases have acidic pH optima, generally near 4.5 ("acid" glycosidases), some of them have apWoptimum near the neutrality (for instance about 6.5) when they show several forms.
They exhibit a wide specificity on the substrates.
Their main subcellular location is in lysosomes, however, they are found in other intracellular and extracellular compartments.
A. Lysosomes and biosynthesis ofycosidases
There are several glycosidases which are located not only in lysosomes but also in other locations; for example, o-D-mannosidase, in lysosomes, Golgi apparatus and cytosol; -D-glucuronidase in lysosomes and endoplasmic reticulum, at least. 549 From the earliest reports of De Duve (8) and coworkers on the role of lysosomes on cell pathology, a large number of publications have appeared on this matter which have been summarized in several reviews (9) (10) (11) (12) (13) (20) , derived from a fortuitous observation appreciated by them in 1968, it has been established that for many plasma glycoproteins sialic acid is essential for their continued tiability in the circulation, since on treating the glycoprotein with sialidase "galactose is exposed as the terminal nonreducing sugar of the protein-linked carbohydrate chains and serves as a specific determinant for the hepatic recognition of the sialic-deficient molecules. Conversely, the presence of intact sialic acid residues on the receptor sites of the hepatic plasma membrane is an absolute requirement for the initial binding reaction, wich in turn is a prelude to macromolecular transport and lysosomal catabolismt' (20) .
Diagnostic potential ofglycosidases in acquired diseases
The purified rabbit liver receptor is also a "glycoprotein in which 10% of the dry weight consisted of sialic acid, galactose, mannose and glucosamine. The presence of calcium and the integrity of the terminal sialic acid residue were shown to be absolute requirements for binding" (23), "since the original discovery of the hepatic receptor for galactose-termined proteins, at least four alternate recognition systems have been described that are dependent on the exposure of specific sugars. These include the mannose-Nacètilglycosamine receptor in the reticuloendotelial system, the fucose receptor in mammalian hepatocytes,the N-acetylglucosamine receptor in avian l±ver.andthe mannose-6-phosphate:receptor in liver and fibroplasts. The latter system has assumed particular importance in that it appears to regulate the appropriate localization of the acid glycosidases within the lysosome" (22) .
Although a relatively high number of papers and review articles (23, (45) (46) (47) (48) (49) (50) (51) (52) (53) have been published on the clearance of lysosomal glycosidases and the role of receptors in these processes, some different points of view can be maintained on these topics. A cross situation for a-D-mannosidase (54) and o-D-glucosidase should be outlined since both enzymes participate in both biosynthesis and catabolism of glycoproteins.
It seems that glycosidases turnover is heterogenous since the measured degradation rates of the different individual enzymes are different; on the other hand, no correlation between half-life and molecular size has been found; furthermore, protein and carbohydrate moiety turn over as a unit, being the turnover relatively slow (55) .
The constitutive and triggered lysosomal enzyme secretion (56), as well as the influence of exogenous amines on endocytosis, has also been recently reviewed (57 veral hydrolases such as -N-acetylhexosaminidase, a-N-acetylhexosaminidase, -galactosidase, -glucuronidase, c-glucosidase and cathepsin D are synthesized as precursors. The activation of the precursor is correlated by a reduction in its size in the case of cathepsin D; however, the precursor of -N-acetylhexosaminidase A is able to hydrolyse GM2 ganglioside on the presence of an activator (58).
In 1973, Li and coworkers (59) observed that crude -N-acetylglucosaminidase A from human liver hydrolyzed glycophingolipids better than its purified preparations; this fact was due to the participation of an activator, identified by Li et al. in 1974 as a protein of 21 K-Da, Li and Li (59) concluded that human liver contains two different activators, one for GM1 ganglioside degradation and other for GM2 degradation. Other authors have also studied other activators from other organs (spleen, brain) which activate other gly-cosidases (60).
Conzelmann et al. (61) have demonstrated that the activator protein extracts glycolipid monomers from micelles to give water-soluble complexes, being able in the absence of enzyme of transporting glycolipids from donor to acceptor membranes. So, deficiencies in hydrolases or in activator proteins could produce lipid storage disorders (62) . On the other hand, it has been recently concluded that the carbohydrate moiety of some glycoproteins such as fibronectin plays an important role in stabilization or protection of the protein components against proteolysis (63) .
Furthermore, the combined deficiency of -galactosidase and neuraminidase in human fibroblasts is caused by the genetic deficiency of a 32 K-Da "protectiye protein" (which is also a glycoprotein); the addition of this factor can correct the excesive intralysosomal catabolism of the lysosomal -galactosidase (64, 65) . It seems that this intralysosomal protection is carried out by aggregation of multimeric -galactosidase, neuraminidase and protective factor (66) .
Precursors of lysosomal enzymes, proteins which collaborate in their activity (activators) and glycoproteins which protect or stabilize them -as well as receptors for targetting, and targetting-ligands of the lysosomal enzymes-are probably efficient factors modulating the function of these enzymes by different and probably complementary mechanisms. Therefore the deficiencies in someone of these mechanisms will have an influence on the enzyme activity determined in any biological material.
CIRCUMSTANCES AND FACTORS INFLUENCING THE ACTIVITY OF LYSOSO-MAL ENZYMES IN BIOLOGICAL. FLUIDS
The group of lysosomal storage diseases will not be the matter of the present study. Several reviews on this subject have been published (3, (67) (68) (69) . Let us only deduce that in the lysosomal storage diseases one or more lysosomal enzymes, or isoenzymes or activator or protective factors, are deficient or absent. Furthermore, it seems that the dysfunction arises rather from an accelered rate of degradation than from an alteration in its synthesis and transport, in several storage diseases, according to Jessup et al. (55) .
Since glycoproteins are mainly degraded by hydrolases present in the lysosomes inside the cell, and glycosidases and proteases occur at higher concentration gradients intracellularly respective to extracellularly (see later), the rise of these enzyme activities in biological fluids such as serum, plasma or urine is a not well understood matter, although it is, paradoxically, the basis supporting a great number of enzyme determinations accomplished in these fluids with a diagnostic finality.
Both points require some discussion:
Lysosomal enzymes are found into the cell at high levels, and normally at low, levels in the plasma and other fluids where they come after exocytosis from the cell. In addition, enzyme actiy4y is measured in the biological fluids, not enzyme concentration. ThIevels of this activity in such fluids reflect the following balance:
Enzyme biosynthesis (+ Activation for drugs,etc1
Enzyme degradation (+ Inactivation for drugs, poisons ,enzyme "ageing", etc.) (The low volume of samples and their dilution generally reduce the influence of drugs, etc, as activators or inhibitors in the determination of enzyme activity).
Alterations in this normal balance, with a rise in the levels of enzyme in extracellular fluids, could be the result of (I) pthological circumstances. For instance:
1. A cellular proliferation, with or without modification of the membrane permeability. 2. An increased permeability of the citoplasma and/or lysosomal membranes, the cell number being normal.
Several agents or situations can modify the citoplasmic membrane giving either necrose or light changes in the permeability: (c) Deficiencies in oxygen supply, depletion of circulating glucose or agents which block any metabolic pathway needed for ATP biosynthesis (since ATP is required for the membrane functions).
Other authors (70, 71) have also summarized some interpretations on the mechanisms of hydrolases leakage.
II. In addition to those pathological circumstances, other, poloic circumstances, should be taken into consideration, such as:
1. The concentration gradient of the enzy,which varies for the enzymes, but may be 3,OO-5OOO-fold higher inside the cell than extracellularly. 2. The size of the enyme molecule, ranging from low to high values.
(It explainsthat enimes such as amilase, the mol. weight of which is relatively low, 45,000, can be eas ly excreted by urine).
3. The intracellular location of the enz.
Briefly, enzymes at a high concentration gradient in the cell, or not associa ted to membranes or with low mol. weight can pass through the semi-permeable barrier which is the citoplasmic membrane better than others, and be finally found in the plasma at higher concentrations than others. In addition, other factors or circumstances (such as the turnover) influence those levels.
Finally, generalcr±itertato select enzymes with analytical application could be the specificity, sensitivity ãnd reptaucibility of the techniques employed, and the period of apparition and length of the modifications of the enzyme activity for one metabolic disorder.
RESULTS OBTAINED ON SEVERAL GLYCOSIDADES IN SERUM AND URINE FROM PATIENTS OF SOME ACQUIRED DISEASES
Although lysosomal enzymes play an important role in clinical research and lysosomes were discovered at the middle of the fifties, the number of papers on this area was relatively low until the eighties. The availability of new commercial substrates has probably encouraged these investigations. At present, the colorimetric assays using substrates such as p-nitrophenyl glycosides have been replaced by the fluorimetric ones employing methylumbelliferyl glycosides because of the generally higher sensitivity of the fluorimetric techniques relative to the spectrophotometric determinations. In values underlined as -the difference was highly significant (2.c0. 001).
A. Results concerning serum glycosidases The values are significantly higher in sera from patients, relative to controls, for many enzyme activities; however, there are also some activities which are significantly lower than controls; and other, finally, which are similar in both groups. Table 1 The data of Table I We have not a definitive answer to these questions. However, all factors discussed before could help us to find a partial interpretation to these facts. Thus,one alteration in the cell membrane (produced by very different agents or circumstances) could be responsible for the release of intralysosomal enzymes into the blood; this release could be accomplished for some enzymes more easily than for ethers depending on their mol. weight and subcellular location. In addition, other interpretations such as those referring to modifications in the receptors, alteration in the turnover of the enzymes, etc, are not precluded.
In connection with this matter, Stahl and coworkers (77) have found that the injection of organophosphatesto rats elicits a massive increase in plasma -glucuronidase, correlated with a fall in its microsomal activity, and independent of protein synthesis; nevertheless, the plasma activity of other lysosomalenzymes remains unchanged; these autors suggest that microsomal -glucuronidase must be modified before secretion by a post-translational mechanism.
Results similar to ours have been generally found also by other authors (78, 79) for glycosidases in patients with leukemia (78) and Grave's disease (79) In addition, the results concerning other disorders for -1-acetylhexosaminidase, which is the serum (or plasma) enzyme with the highet activity of the glycosidases commonly determined, are also in agreement with ours; so, in diabetes, myocardial infarction and liver diseases (80) , varicous states (81), diabetes (82) (83) (84) and liver disorders (85,86).
From a few years, the studies on lycosidase isoenzymes (see reviews 87-89) have demonstrated to be of great interE.Theviews (90) concerning hexosaminidase isoenzymes and papers (91-95). on their properties and determination have appeared. Probably in a next future, the measure of total activity of some glycosidases should be accompanied by that of their isoenzymes in view of getting a better information on many lysoomal.diseases. a-L-Fucosidase is another glycosidase whose levels are relatively high in several disorders. Precisely a paper on the advantages of the fluorimetric determination cy this enzyme and its forms was published as early as 1974 by Robinson and Thorpe (96). The presence of low and high activity forms of o -L-fucosidase in normal human serum is a peculiarity of this enzyme which has been studied by some authors (94-103L. Its substrate specificity (104) and levels in diabetics (105) have also been studied. -D-Fucosidase is a special activity corresponding to a well characterized enzyme (2) which shows a wide variability in its properties concerning the association to other activities ( -D--galactosidase, -D-glucosidase); however, their values in sera from patients of some illness do not seem to be paired with those of -D-galactosidase and -D-glucosidase (see. Table 1 ).
B. Usefulness of those determination for following the course land detection of some diseases. There are few publications on glycosidases as a measure for following the course of a disease. We have determined the activity of glycosidases in sera from 21 convalescent patients who ingested a toxic oil, taking tne blood samples on 3 or 4 occasions during a period of 11-12 months (108), and pursuing a previous study in which the same patients were atcthe acute phase of their illness (75, 76) . The enzyme activities which were higher than controls during the first 1-3 months of the study decreased after few months and became normal, while those which were initially lower, increased and finally were similar (or higher) to controls, being all these results correlated with the improvement in the general health state of the patients (108).
Another important topic is that concerning the eventual use of some glycosidase determinations in preventive medicine for detection of pathological situations not declared by typical symptoms. The rapport of Tettamanti and cor workers (107) is particulary illustrative on the study of workers exposed to inorganic mercury vapours as well as on the assay and significance of enzymes of lysosomal origin in plasma (or serum).
C. Results concerning urine glycosidases
In some cases, the general characteristics of urine reduce its use for enzyme analysis. However, the determination of glycosidases (mainly -N-acetylhexominidase and its isoenzymes) in urine is very interesting in the research Of renal disorders or after renal transplantation or for following the nephrotoxicity caused by amino glycosidic antibiotics. Besides, it can be performed by automatic procedures (109).
One excellent review on urinary enzymes, nephrotoxicity and renal diseases is that of Price (110) . Other recent papers relative to these topics are: On the use of w-nitrostyryl substrates for colorimetric assays in urine (111), glycosidases in hypertension (112), in urinary tract infections (113), in diabetes (114), after renal transplantation (115, 116),in multiple myeloma (117) and for evaluating nephrotoxicity of aminoglycosides or other substances (118) (119) (120) D. Practical suggestions 1. The comparison of the results from different (or from the same) laboratories is very often a difficult task due to the use of. different analytical procedures or assay conditions. In addition, the expression of the enzyme activity values is not uniform. Thus, it would be very convenient to normalize the experimental protocols for these enzymes. Actually the detailed description of some common techniques, for example those concerning -N-acetylhexosa minidase (121) and 0-L-fucosidase (1221, are easy to find.
2. The stabiliy of glycosidases seems to be generally higher in plasma than in serum, acording to Lombardo et al. (1231; in contrast, the kind of anticoagulant does not seem to influence the plasma activity values (123). Therefore Lombardo and coworkers propose to employ plasma and not serum for these analysis and to perform the assays "with freshly prepared plasma no later than 1 h after its preparation" (124). A great progress has been achieved during approximately the last ten years in the knowledge on plasma, serum and urine glycosidases related to some acquired diseases; but further research is required to develop this knowledge and to avoid limitations such as those caused by overlapping of some experimental and control results, etc.
2. However, from the data discussed above, it seems that the determination of some glycosidase activities (mainly 3-N-acetylhexosaminidase) and their isoenzymes in plasma (or serum), and urine (for the study of renal disorders), is interesting and should be performed more frequently, at least in some research laboratories in which other enzyme activities are measured with a clinical finality, as a previous step to generalize their use in the routinary work of Clinical Enzymology. 
